---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-006021"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2026-01-23T23:59:59+00:00"
generated_at: "2026-05-16T08:27:40.895451+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NextCure reports $41.8M cash; SIM0505 data Q2 2026, LNCB74 delayed to H2 2026

## Summary
- Preliminary cash, cash equivalents and marketable securities of $41.8M as of Dec 31, 2025; runway into H1 2027.
- SIM0505 (CDH6 ADC) Phase 1 dose escalation data expected Q2 2026; dose optimization starts H1 2026.
- LNCB74 (B7-H4 ADC) higher dose cohorts underway; proof-of-concept data delayed from H1 to H2 2026.
- Both programs target gynecological cancers; LNCB74 now includes adenoid cystic carcinoma.

## SEC filing metadata
- accession: 0001104659-26-006021
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2026-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465926006021/0001104659-26-006021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465926006021/nxtc-20260123x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-006021
- JSON: https://secwatch.observer/filing/0001104659-26-006021.json
- Plain text: https://secwatch.observer/filing/0001104659-26-006021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.